SOLUTION

Life Sciences

We support CROs and biopharma with AI-powered solutions to identify novel pathology-based biomarkers that can accelerate drug development.

With our AI platform, we provide CROs and biopharma with AI-powered solutions to identify novel pathology-based biomarkers that can accelerate drug development.

Aiosyn’s algorithms can be used to accelerate the development of biomarker-based therapeutic and patient stratification strategies

Selection of AI solutions

Lymphocyte detection

Detection of lymphocytes in immunostaining CD3, CD8, FoxP3, etc.

Ki-67 quantification

Detection of tumor cell growth in Ki-67 immunostaining.

Mitotic figure counting

Detection of mitotic figures in H&E sections.

Workflow

AI brings speed and accuracy

Our technology harnesses a powerful form of machine learning called “neural networks” (or deep learning) to identify abnormal tissue patterns such as cancer. Artificial intelligence has shown to do this with unprecedented accuracy and speed. For quantifying patterns and cells of interest, AI offers consistent quality, repeatability, and speed.

Contact us

Experience our AI-powered pathology algorithms

Contact with our team to experience our AI-powered pathology algorithms can help you with pathology workflow, clinical diagnostics and/or drug development programs.